Registered Trademarks
The "NuAge" and "恆創" brands are now registered in key jurisdictions worldwide, securing our market exclusivity. A substantial portfolio of additional trademark applications is also pending in numerous other countries, reflecting the breadth of our comprehensive global strategy.
Signed Agreements
On December 11, 2025, NuAge (Shaanxi) Medical and Technology Company Ltd and China Rongtong Scientific Research Institute Group Co., Ltd. formally signed a Technology (Patent Rights and Technical Know-how) Transfer Agreement, acquiring the patent rights and technical know-how related to the “Anti-GDF15 Neutralizing Monoclonal Antibody” program for oncology immunotherapy. The project has been listed on the Shanghai Technology Exchange (Listing No.: Z202250159) and has completed the required review procedures in accordance with applicable regulations.
The project has been listed on the Shanghai Technology Exchange (Listing No.: Z202250159) and has completed the required review procedures in accordance with applicable regulations.
Signing Representatives
NuAge (Shaanxi) Medical and Technology Company Ltd — Legal Representative (Dr. Antony Poon)
China Rongtong Scientific Research Institute Group Co., Ltd. — Authorized Agent
This agreement marks a critical step in the industrialization of the GDF15 antibody program, laying a solid foundation for subsequent drug development and market adoption, and demonstrating meaningful progress in NuAge’s strategic deployment in oncology immunotherapy.
Brand Recognition
Hong Kong License Plate:「NUAGE」
This comprehensive global framework signifies that NuAge is fully prepared for market expansion, providing a secure and recognizable foundation for introducing our world-class products to patients and consumers worldwide.
